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Abstract 
 
Background: Trichomoniasis is a worldwide protozoan parasitic disease and metronidazole is a 
choice drug for its treatment. Because of disease importance in public health and its controversial 
ideas about the prevalence of drug resistance, this study was carried out. 
Methods: Fifty-two suspected vaginal samples were collected from 2006 to 2007 in Gynecology 
Maryam Hospital, Tehran, Iran. All isolates were examined by microscopic, culture and PCR 
techniques. The PCR products were analyzed by RFLP and CSGE methods and two suspected 
samples were sequenced. 
Results: Trichomonas vaginalis was identified from all 52 samples. Of 52 isolates, 45 samples 
were successfully cultured and amplified by PCR except one. Seven were positive only by PCR. 
Finally, ITS1 fragment was successfully amplified in 51 of 52.  CSGE analysis and PCR products 
digestion by MspI followed by sequencing showed nucleotide mutation at position 209 (C209T) 
of the ITS1 fragment in two (3.9%) of them. 
Conclusion: The results showed mutation in ITS1 fragment of T. vaginalis in two (3.9%) of Ira-
nian isolates which may be related to metronidazole resistance. 
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richomoniasis is the most widespread 
non-viral sexually transmitted disease 
caused by T.  vaginalis (1). 
The clinical disease in women ranges from 
asymptomatic to symptomatic such as severe 
urethritis,  vulvo-vaginitis,  cervicitis  (2), 
birth  of  preterm  or  low-birth-weight  infant 
and  possibility  of  development  of  cervical 
cancer  are  associated  complication  in  af-
fected women (3,4). The infected women are 
more  susceptible  to  other  transmitted  dis-
eases  including  HIV  (5).  One  of  the  most 
significant clinical features of T. vaginalis is 
resistance to choice drug, metronidazole (6-
8)  which  was  recognized  as  an  effective 
treatment  with  cure  rate  of  approximately 
95% (9). 
Metronidazole  resistance  has  been  reported 
since 1962 (10) and some studies have been 
reported from 2.5% - 5% (11, 12). More than 
10% of infected patients in the United States 
does not respond to this drug (13), and some 
clinical isolates have showed decreasing sus-
ceptibility to metronidazole (14). Rasoloson 
et al. showed mechanism of in vitro develop-
ment  of  resistance  to  metronidazole  in  T. 
vaginalis( 15). Meri et al. reported the first 
three  cases  of  metronidazole  resistant  T. 
vaginalis from Finland (16). Resistance test-
ing was performed for 78 of 467 isolates of 
T. vaginalis, 4 ones were resistance to differ-
ence  concentrations  of  metronidazole  (17). 
Clinical metronidazole resistance is defined 
by  failure  infection  clearance  by  standard 
treatment  (8).  Internal  transcribed  spacers 
(ITS1 and 2) are nonfunctional fragments in 
ribosomal RNA between 18s rRNA and 28s 
rRNA and found in all eukaryotic organisms 
which  are  transcribed,  but  not  translated. 
Some  investigators  proposed that  it  has  an 
important  role  in  using  metronidazole  as 
choice  treatment  (8).  Identification  of  the 
molecular methods to detect drug resistance 
may lead to faster results for clinical treat-
ments (18). 
This study was designed for the first time in 
Iran for mutation detection in ITS1 gene of T. 
vaginalis by molecular methods. 
 
Materials and Methods 
 
Sampling 
As a descriptive study on fifty two vaginal 
samples  were  collected  from  both  treated 
and  untreated  women  suspected  to 
trichomoniasis  that  referred  to  Gynecology 
Department of Maryam Hospital  in Tehran 
from  2006  to  2007.  Wet  mounts  examina-
tions were done for all samples and all were 
cultured in 50 ml of TYM medium (19). 
 
DNA extraction 
Cultures were centrifuged at 430 ×g for 20 
min  at  4°C  and  pellets  were  washed  once 
with PBS (pH 7.4). Total nucleic acid was 
extracted with the Prim Prep Genomic DNA 
Isolation Kit (GeNet Bio company, Chung-




The  ITS1  fragment  was  amplified  by  de-
signed  primers  based  on  T.  vaginalis  ribo-
somal  DNA  (rDNA)  gene  (ACCESSION 
AF466750).  TVITS F: 5´- ACA CCG CCC 
GTC  GCT  CCT  AC  -3´  and  TVITSR:  5´ 
AAT TTG CAT TCA AAG ATT AAC- 3´. 
These primers were amplified 313 bp of T. 
vaginalis ITS1. The PCR reaction contained 
500  ng  DNA,  12.5  µl  master  mixes  (Am-
pliqon, California, US) and 20 pmol of each 
of the forward and reverse primers in 25 µl 
of final volume. PCR reactions were carried 
out in 30 cycles, denaturation at 94
oC for 30 
sec, annealing at 52
oC for 30 sec and exten-
sion  at  72
oC  for  30  sec.  The  reaction  was 
incubated for 5 min. at 94
oC and 72
oC as pre 
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denaturation  and  post  extension  steps, 
respectively.  The  PCR  products  were  sub-
jected  to  electrophoresis  using  2%  agarose 
gel, stained by ethidium bromide and visual-
ized under a UV transilluminator. 
 
PCR product analysis 
All PCR products were analyzed by CSGE 
method  (20)  and  RFLP  using  digestion  by 
MspI  restriction  enzyme.  The  CSGE  is  a 
universal  mutation  detection  system  was 
developed  for  study  into  rapid  and  non-
radioactive heteroduplex based detection for 
mutation  screening.  PCR  products  were 
mixed by control PCR product, subjected to 
5 min at 98 °C and 30 min at 68 °C, mixed 
by five µl of loading buffer (30% glycerol, 
0.25%  bromophenol  blue  and  0.25%  xylen 
cyanol FF), and subjected to electrophoresis 
on 10% CSGE gel. The PCR products were 
digested with MspI restriction enzyme for 3h 
at 37
oC in the appropriate buffer and restric-




After  investigating  T.  vaginalis  isolates  by 
three  methods  including  direct  smear,  cul-
ture in TYI and PCR, 44 isolates were posi-
tive in both culture and PCR but seven were 
positive  only  by  PCR.  The  ITS1  fragment 
was amplified by PCR in 51 of 52 DNA ex-
tractions. Figure 2 showed 2% agarose gel 
electrophoresis of amplified 313 bp as PCR 
product.  
All the 51 PCR products of T. vaginalis iso-
lates were electrophoresed on CSGE gel and 
two PCR products were suspected. The sus-
pected samples were purified and sequenced 
by  dideoxy  chain  termination  method.  Our 
results demonstrated mutation in ITS1 frag-
ment in two cases (3.9%) that were sympto-
matic and none of them used metronidazole 
before  examination.  Both  sequences  were 
aligned  in  GenBank  by  Blast  software  and 
demonstrated  mutation  related  to  aligned 
genes in GenBank.  
The all-51 amplified PCR products were di-
gested  by  MspI  restriction  enzyme  and 
electrophoresed on 3% agarose gel.  Figure 3 
showed RFLP pattern of mutant wiled sam-
ples on agarose gel.  Sequence of  mutated 
samples submitted to GenBank at accession 
numbers  EU308571  and  EU308572.  The 
results  showed  mutation  at  position  209 
(C209T)  of  the  ITS1  region  in  which  the 
thymidine  was  replaced  by  cytosine  in 














Fig. 3: Agarose gel electrophoresis of RFLP 
pattern. Lane 1. PCR Product (313bp).  Lane 
2. 100 bp DNA Ladder marker. Lane 3. 
MspI digested wild type PCR Product (270 
bp). Lane 4. MspI digested mutant type PCR 




The  purpose  of  this  study  was  detection 
mutations  in  ITS1  of  T.  vaginalis  isolated 
from  Iranian  patients.  Although  correlation 
between metronidazole resistance and ITS1 
mutations have been reported among clinical 
isolates  of  T.  vaginalis  (8),  but  others  re-
ported that correlation between the ITS1 se-
quence  variations  and  drug  resistance  was 
not  observed  and  may  be  related  to  My-
coplasma hominis (21). Previous studies re-
ported relationship between ITS1 mutations 
and drug resistance, but they showed differ-
ent results. The mechanism of metronidazole 
resistance in T. vaginalis from treatment fail-
ure is not clear (22). Additional studies are 
needed  to  adapt  the  differences  between 
these  studies.  Internal  transcribe  spacer 
(ITS) has been considered as an appropriate 
candidate  gene  for  determination  of 
metronidazole susceptibility on T. vaginalis, 
the  sequence  of  this  gene  have  conserved 
among related species (21). 
Despite its high prevalence, the genetic vari-
ability  and  drug  resistance  features  of  this 
parasite  are  poorly  understood.  The  muta-
tions in genomic level (like ferredoxin muta-
tion) are the important cause of drug resis-
tance phenomenon (23). Butler and Xioa in 
two separate studies showed 51% and 14% 
resistance to metronidazole in vitro respec-
tively (18, 21). In other study Upcroft et al., 
using PCR, showed 17.4% resistance to met-
ronidazole  (24).  Due  to  different  methods, 
our  results  were  different  from  mentioned 
studies. 
This suggests that single mutation on ITS1 
gene may be a marker for identify resistance 
that  could  lead  to  control  and  treatment 
strategies  to  avoid  from  prevent  of  their 
distribution. Clearly, further studies with lar-
ger samples from different endemic regions 
are needed to explain this contradiction. 
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